ICI treatment outcomes of metastatic AM and MM with MDM2/4 or EGFR amplifications have been studied; the association between hyper-progression and MDM2/4 or EGFR amplification in these AM/MMs was not statistically significant [58]. This evidence concerns the gene MDM2 and Miyoshi myopathy.